Nifty Pharma Falls Nearly 2%; Sun Pharma, Cipla, Dr Reddy's Slide After Trump's Generic Drug Tariff Proposal

The Nifty Pharma index fell nearly 2% in early trade on Wednesday after US President Donald Trump proposed a phased tariff regime for imported generic medicines, triggering broad-based selling in pharmaceutical stocks with significant exposure to the US market.

At 11:30 am IST, the Nifty Pharma index was down 1.9% at 25,783.35, after falling as much as 2% to an intraday low of 25,550.70. Nineteen of the index's 20 constituents traded in the red.

The broader market was also under pressure. The Sensex declined 390.62 points, or 0.5%, to 77,079.49, while the Nifty 50 slipped 100.95 points, or 0.42%, to 24,086.75. India VIX gained 3.8%, signalling increased market volatility.

Sun Pharma, Cipla, Dr Reddy Lead Losses

Aurobindo Pharma led the decline, falling as much as 2.6% in early trade. Glenmark Pharma and Zydus Lifesciences lost around 2.5% each, while Lupin also traded lower by about 2.5%.

Shares of Cipla, Sun Pharmaceutical Industries and Dr Reddy's Laboratories also declined, with all three featuring among the top losers on the Nifty 50. Biocon, Divi's Laboratories, Mankind Pharma, Ajanta Pharma, Alkem Laboratories and Gland Pharma also traded in the red.

The sell-off followed concerns that higher US import duties could increase costs for overseas manufacturers and eventually reshape supply chains in the world's largest pharmaceutical market.

Trump Outlines Phased Tariff Plan

Trump unveiled the proposal in a post on Truth Social, outlining a staggered tariff structure for imported generic medicines.

Under the plan, generic drugs imported into the United States would continue to attract zero tariffs until August 2028, following a two-year transition period beginning August 1, 2026. Import duties would then rise to 100% for one year before increasing to 200% thereafter.

Trump said the proposal is intended to encourage pharmaceutical companies to establish manufacturing facilities in the United States. He added that the administration's policy on patented, branded and innovative medicines would remain unchanged.

Why Investors Are Paying Attention

The United States is the largest overseas market for many Indian pharmaceutical companies, particularly manufacturers of generic medicines.

Companies including Sun Pharma, Dr Reddy's Laboratories, Cipla, Lupin, Aurobindo Pharma and Zydus Lifesciences generate a meaningful share of their revenue from the US market. While the proposal is yet to be implemented, investors are assessing whether higher import duties could affect future manufacturing strategies, export competitiveness and long-term earnings.

India is also one of the world's largest suppliers of generic medicines. According to Union Minister of State for Health and Family Welfare Anupriya Patel, India accounts for nearly 30% of global generic medicine supplies.

The proposed tariffs also come as Indian drugmakers expand into newer export markets. The recently signed India-UK Comprehensive Economic and Trade Agreement (CETA) is expected to improve market access for Indian pharmaceutical companies by eliminating tariffs on most products. However, the United States remains the sector's largest export destination, making developments in US trade policy particularly significant.

Investors will now watch for further details from the US administration on the implementation of the proposed tariff regime, including whether different categories of generic medicines or pharmaceutical ingredients receive separate treatment.

Also Read - Trump Unveils Tariff Roadmap For Generic Drugs; 0% For 2 Years, Then 100% And 200% Later